Application of a novel and noninvasive skin sampling technique for analyzing cytokine-mediated inflammation in rosacea

Journal of Toxicology - Cutaneous and Ocular Toxicology

Volumn 22, Issue 1-2, 2003, Pages 13-22

  Robinson, Michael K ^a   Schwartz, Jamie F ^a   Perkins, Mary A ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Cytokine; Inflammation; Noninvasive; Rosacea; Skin

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; SURFACTANT;

ADSORPTION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DANDRUFF; DIAPER DERMATITIS; DISEASE SEVERITY; FASCIA; FEMALE; HUMAN; HUMAN TISSUE; MALE; ROSACEA; SAMPLING; SCALP; SEBORRHEIC DERMATITIS; SKIN; SKIN INFLAMMATION; ULTRAVIOLET RADIATION;

ROSACEA;

EID: 0037731598     PISSN: 07313829     EISSN: None     Source Type: Journal    
DOI: 10.1081/CUS-120019326     Document Type: Article

References (31)

1. Fregert S. Manual of Contact Dermatitis. Chicago: Year Book Medical Publisher, 1981.
2. Kligman AM. The invisible dermatoses. Arch Dermatol 1991; 127:1375-1382.
3. Serup J, Jemec GBE. Handbook of Noninvasive Methods and the Skin. Boca Raton: CRC Press, 1995.
4. Gerberick GF, Rheins LA, Ryan CA, Ridder GM, Haren M, Miller C, Oelrich DM, Vonbargen E. Increases in human epidermal DR(+)CD1(+), DR(+)CD1(-), CD36(+), and DR(-)CD3(+), cells in allergic versus irritant patch test responses. J Investig Dermatol 1994; 103:524-529.
5. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 1994; 30:535-546.
6. Ryan CA, Gerberick GF. Cytokine mRNA expression in human epidermis after patch treatment with rhus and sodium lauryl sulfate. Am J Contact Dermatol 1999; 10:127-135.
7. Morhenn VB, Chang EY, Rheins LA. A noninvasive method for quantifying and distinguishing inflammatory skin reactions. J Am Acad Dermatol 1999; 41:687-692.
8. Hirao T, Aoki H, Yoshida T, Sato Y, Kamoda H. Elevation of interleukin 1 receptor antagonist in the stratum corneum of sun-exposed and ultraviolet B-irradiated human skin. J Investig Dermatol 1996; 106:1102-1107.
9. Terui T, Hirao T, Sato Y, Uesugi T, Honda M, Iguchi M, Matsumura N, Kudoh K, Aiba S, Tagami H. An increased ratio of interleukin-1 receptor antagonist to interleukin-1 alpha in inflammatory skin diseases. Exp Dermatol 1998; 7:327-334.
10. Perkins MA, Farage MA, Wong TK, Robinson MK. Development of noninvasive method for assessing human skin irritation. Fundam Appl Toxicol 1997; 36:365.
11. Perkins MA, Osterhues MA, Farage MA, Robinson MK. A noninvasive method to assess skin irritation and compromised skin conditions using simple tape adsorption of molecular markers of inflammation. Skin Res Technol 2001; 7:227-237.
12. Perkins MA, Cardin CW, Osterhues MA, Robinson MK. A noninvasive method for recovery of inflammatory mediators to differentiate normal from compromised scalp conditions. Skin Res Technol 2002; 8:187-193.
13. http://www.rosacea.org.
14. Helm KF, Menz J, Gibson LE, Dicken CH. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol 1991; 25:1038-1043.
15. Barton K, Monroy DC, Nava A, Pflugfelder SC. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology 1997; 104:1868-1874.
16. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg 2001; 20:199-206.
17. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 1994; 30:535-546.
18. Brink N, Szamel M, Young AR, Wittern KP, Bergemann J. Comparative quantification of IL-1 beta, IL-10, IL-10r, TNF alpha and IL-7 mRNA levels in UV-irradiated human skin in vivo. Inflamm Res 2000; 49:290-296.
19. Man MQ, Wood L, Elias PM, Feingold KR. Cutaneous barrier repair and pathophysiology following barrier disruption in IL-1 and TNF type I receptor deficient mice. Exp Dermatol 1999; 8:261-266.
20. Perkins MA, Osborne R, Rana FR, Ghassemi A, Robinson MK. Comparison of in vitro and in vivo human skin responses to consumer products and ingredients with a range of irritancy potential. Toxicol Sci 1999; 48:218-229.
21. Jung T. New treatments for atopic dermatitis. Clin Exp Allergy 2002; 32:347-354.
22. Asadullah K, Sterry W, Trefzer U. Cytokine therapy in dermatology. Exp Dermatol 2002; 11:97-106.
23. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis - the new therapeutic frontier. Arch Dermatol 2002; 138:657-663.
24. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis - a report of 2 cases. Arch Dermatol 2002; 138:644-648.
25. Marks R. Histogenesis of the inflammatory component of rosacea. Proc R Soc Med 1973; 66:742-745.
26. Barton K, Nava A, Monroy DC, Pflugfelder SC. Cytokines and tear function in ocular surface disease. Adv Exp Med Biol 1998; 438(461-9):461-469.
27. Hirao T, Aoki H, Ichikawa H, Sato Y. Characterization of an interleukin 1 receptor antagonist protein released from ultraviolet-irradiated epidermal sheet. J Dermatol Sci 1997; 14:189-198.
28. Hauser C, Saurat JH, Schmitt A, Jaunin F, Dayer JM. Interleukin 1 is present in normal human epidermis. J Immunol 1986; 136:3317-3323.
29. Uchi H, Terao H, Koga T, Furue M. Cytokines and chemokines in the epidermis. J Dermatol Sci 2000; 24(suppl 1):S29-S38.
30. Deboer OJ, Wakelkamp IMMJ, Pals ST, Claessen N, Bos JD, Das PK. Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch Dermatol Res 1994; 286:304-311.
31. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther 2001; 18:237-243.